TY - JOUR
T1 - Platelets from HIV-infected individuals on antiretroviral drug therapy with poor CD4+ T cell recovery can harbor replication-competent HIV despite viral suppression
AU - Real, Fernando
AU - Capron, Claude
AU - Sennepin, Alexis
AU - Arrigucci, Riccardo
AU - Zhu, Aiwei
AU - Sannier, Gérémy
AU - Zheng, Jonathan
AU - Xu, Lin
AU - Massé, Jean Marc
AU - Greffe, Ségolène
AU - Cazabat, Michelle
AU - Donoso, Maribel
AU - Delobel, Pierre
AU - Izopet, Jacques
AU - Eugenin, Eliseo
AU - Gennaro, Maria Laura
AU - Rouveix, Elisabeth
AU - Bordé, Elisabeth Cramer
AU - Bomsel, Morgane
N1 - Publisher Copyright:
© 2020 The Authors.
PY - 2020/3/18
Y1 - 2020/3/18
N2 - In addition to hemostasis, human platelets have several immune functions and interact with infectious pathogens including HIV in vitro. Here, we report that platelets from HIV-infected individuals on combined antiretroviral drug therapy (ART) with low blood CD4+ T cell counts (<350 cells/μl) contained replication-competent HIV despite viral suppression. In vitro, human platelets harboring HIV propagated the virus to macrophages, a process that could be prevented with the biologic abciximab, an anti-integrin αIIb/β3 Fab. Furthermore, in our cohort, 88% of HIV-infected individuals on ART with viral suppression and with platelets containing HIV were poor immunological responders with CD4+ T cell counts remaining below <350 cells/μl for more than one year. Our study suggests that platelets may be transient carriers of HIV and may provide an alternative pathway for HIV dissemination in HIV-infected individuals on ART with viral suppression and poor CD4+ T cell recovery.
AB - In addition to hemostasis, human platelets have several immune functions and interact with infectious pathogens including HIV in vitro. Here, we report that platelets from HIV-infected individuals on combined antiretroviral drug therapy (ART) with low blood CD4+ T cell counts (<350 cells/μl) contained replication-competent HIV despite viral suppression. In vitro, human platelets harboring HIV propagated the virus to macrophages, a process that could be prevented with the biologic abciximab, an anti-integrin αIIb/β3 Fab. Furthermore, in our cohort, 88% of HIV-infected individuals on ART with viral suppression and with platelets containing HIV were poor immunological responders with CD4+ T cell counts remaining below <350 cells/μl for more than one year. Our study suggests that platelets may be transient carriers of HIV and may provide an alternative pathway for HIV dissemination in HIV-infected individuals on ART with viral suppression and poor CD4+ T cell recovery.
UR - http://www.scopus.com/inward/record.url?scp=85082016579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082016579&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aat6263
DO - 10.1126/scitranslmed.aat6263
M3 - Article
C2 - 32188724
AN - SCOPUS:85082016579
SN - 1946-6234
VL - 12
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 535
M1 - eaat6263
ER -